A Phase II Study of Daily Thalidomide, Oral Cytoxan and Prednisone for Relapsed or Refractory Multiple Myeloma

Abstracts/Posters/Presentations:

• Rafat Abonour, Kristen Ganjoo, Christopher Fausel, Constantin Yiannoutsos, Beth E. Juliar, Lisa Wood, Gina Smith, Paul Walker, Larry Cripe. A Phase II Study of Oral Cyclophosphamide, Thalidomide, and Prednisone (CTP) for Patients with Relapsed or Refractory Multiple Myeloma, A Hoosier Oncology Group Trial: MM01-21. Accepted as a poster presentation for ASH Annual Meeting December 6-9, 2003, San Diego, CA.
• Final Report of a Phase II Study of Oral Cyclophosphamide, Thalidomide, and Prednisone (CTP) for Patients with Relapsed or Refractory Multiple Myeloma: A Hoosier Oncology Group Trial: MM01-21. Accepted as a poster presentation for the ASCO Annual Meeting, May 13 – 17, 2005, Orlando, FL

Manuscripts/Articles:

• Suvannasankha A, Fausel C, Juliar BE, Yiannoutsos CT, Fisher WB, Ansari RH, Wood LL, Smith GG, Cripe LD, Abonour R. Final report of toxicity and efficacy of a phase II study of oral cyclophosphamide, thalidomide, and prednisone for patients with relapsed or refractory multiple myeloma: A Hoosier Oncology Group Trial, HEM01-21. Oncologist. 2007 Jan;12(1):99-106. See abstract.